2. Anti-infection
  3. Antibiotic Bacterial
  4. Finafloxacin

Finafloxacin is an orally active fourth-generation fluoroquinolone broad-spectrum antibiotic. Finafloxacin exhibits stronger antibacterial activity in acidic pH environments and is not easily affected by bacterial multidrug efflux transporters. Finafloxacin is effective against a variety of extracellular pathogenic bacteria, and can also accumulate in macrophages, showing excellent antibacterial activity against intracellular Staphylococcus aureus, Listeria monocytogenes, Legionella pneumophila, Burkholderia pseudomallei, and other pathogens. Finafloxacin has been approved by the U.S. FDA for research on acute otitis externa mediated by Pseudomonas aeruginosa. Finafloxacin is also used in studies related to diseases such as melioidosis, inhalational tularemia, and inhalational plague.

For research use only. We do not sell to patients.

Finafloxacin

Finafloxacin Chemical Structure

CAS No. : 209342-40-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Finafloxacin:

Finafloxacin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Finafloxacin

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Finafloxacin is an orally active fourth-generation fluoroquinolone broad-spectrum antibiotic. Finafloxacin exhibits stronger antibacterial activity in acidic pH environments and is not easily affected by bacterial multidrug efflux transporters. Finafloxacin is effective against a variety of extracellular pathogenic bacteria, and can also accumulate in macrophages, showing excellent antibacterial activity against intracellular Staphylococcus aureus, Listeria monocytogenes, Legionella pneumophila, Burkholderia pseudomallei, and other pathogens. Finafloxacin has been approved by the U.S. FDA for research on acute otitis externa mediated by Pseudomonas aeruginosa. Finafloxacin is also used in studies related to diseases such as melioidosis, inhalational tularemia, and inhalational plague[1][2][3].

IC50 & Target

Quinolone

 

In Vitro

Finafloxacin (24 h; 48 h) inhibits growth of extracellular MSSA, CA-MRSA, HA-MRSA, VISA, L. monocytogenes, and L. pneumophila with MICs ranging from 0.01 mg/L (against L. pneumophila) to 16 mg/L (against a ciprofloxacin-resistant HA-MRSA isolate), and shows reduced susceptibility to NorA and Lde efflux mechanisms compared to ciprofloxacin[1].
Finafloxacin is bactericidal against intracellular L. monocytogenes in human THP-1 macrophages at neutral pH, but is less potent than ciprofloxacin[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Finafloxacin Related Antibodies
In Vivo

Finafloxacin (23.1 mg/kg; p.o.; every 8 h; 3-7 days) provides 100% survival when administered starting 24 h post inhalational F. tularensis challenge, and 50% survival when administered for 7 days starting 72 h postchallenge, with improved time to death compared to ciprofloxacin in the 3-day delayed regimen[3].
Finafloxacin (23.1 mg/kg; p.o.; every 8 h; 3-7 days) provides 100% survival when administered starting 24 h post inhalational Y. pestis challenge, and 80% to 100% survival when administered starting 38 h postchallenge[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 8 to 10 weeks old, inhalational challenge with Francisella tularensis SCHU S4)[3]
Dosage: 23.1 mg/kg
Administration: p.o.; every 8 h; 3 days; 7 days
Result: Provided 100% survival when treatment initiated at 24 h postchallenge, with 90% of mice showing no clinical signs of disease, no detectable bacteria in organs, and no histopathological changes typical of infection.
Increased time to death significantly compared to ciprofloxacin when treatment initiated at 72 h postchallenge for 3 days, with mice resolving clinical signs by day 7, relapsing by day 11, and succumbing by day 16.
Provided 50% survival when treatment initiated at 72 h postchallenge for 7 days, with all surviving mice having no detectable bacteria in organs and no histopathological changes typical of infection.
Caused less weight loss than ciprofloxacin in the 3-day 72 h postchallenge regimen, with differences identifiable at days 9 to 10 postchallenge.
Molecular Weight

398.39

Formula

C20H19FN4O4
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@]5([H])OCCN[C@@]5([H])C4)=C3C#N)C1=O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 6.4 mg/mL (16.06 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5101 mL 12.5505 mL 25.1010 mL
5 mM 0.5020 mL 2.5101 mL 5.0202 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 98.75%

SDS (393 KB)

COA (251 KB) LCMS (87 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5101 mL 12.5505 mL 25.1010 mL 62.7526 mL
5 mM 0.5020 mL 2.5101 mL 5.0202 mL 12.5505 mL
10 mM 0.2510 mL 1.2551 mL 2.5101 mL 6.2753 mL
15 mM 0.1673 mL 0.8367 mL 1.6734 mL 4.1835 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Finafloxacin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Finafloxacin209342-40-5AntibioticBacterialLegionella pneumophilaPseudomonas aeruginosaBurkholderia pseudomalleiFrancisella tularensisTHP-1 macrophagesLdeStaphylococcus aureusNorAYersinia pestisListeria monocytogenesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Finafloxacin
Cat. No.:
HY-13451
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.